UK biotech startup raises $100M for next-gen vaccines for respiratory viruses
The vaccine market might be a crowded one, but London-based Vicebio aspires to cement its own place within it. The startup announced today it has raised $100mn in Series B funding for the development of its next-generation vaccines for respiratory viruses. Vicebio aims to deliver vaccines that are highly effective, easy to manufacture, and ready-to-use in prefilled syringes. The key to achieving this result lies in using a novel approach called molecular clamp technology. The technology was first invented by Paul Young, Daniel Watterson, Keith Chappell, and their research groups at The University of Queensland in Australia. It is licensed…This story continues at The Next Web
The vaccine market might be a crowded one, but London-based Vicebio aspires to cement its own place within it. The startup announced today it has raised $100mn in Series B funding for the development of its next-generation vaccines for respiratory viruses. Vicebio aims to deliver vaccines that are highly effective, easy to manufacture, and ready-to-use in prefilled syringes. The key to achieving this result lies in using a novel approach called molecular clamp technology. The technology was first invented by Paul Young, Daniel Watterson, Keith Chappell, and their research groups at The University of Queensland in Australia. It is licensed…
This story continues at The Next Web